ABUS
Arbutus Biopharma Corp
4.80$
+1.9%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Cash Flow
Arbutus Biopharma Corp (ABUS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -40 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.7 | -6.8 | -8.4 | -10 | -18 | -27 | -10.0 | -15 | -2.6 | -2.7 | -8.5 | -5.2 | -11 | -7.5 | 33 | -6.7 | -12 | -55 | -58 | -49 | -68 | -71 | -51 | -68 | -35 | -86 | -65 | -40 | |
| 1.0 | 1.3 | 1.3 | 3.9 | 5.6 | 6.8 | 1.2 | 2.4 | 0.6 | 0.4 | 1.1 | 1.9 | 1.0 | 1.0 | 0.9 | 0.6 | 0.5 | 0.6 | 1.1 | 2.0 | 2.2 | 2.0 | 2.0 | 1.8 | 1.4 | 1.4 | 1.4 | 0.4 | |
| – | – | – | – | – | – | – | – | – | 0.4 | – | 0.3 | 0.7 | 0.6 | 1.0 | 0.9 | 3.3 | 22 | 39 | 15 | 6.2 | 6.8 | 6.2 | 6.4 | 7.2 | 9.3 | 9.0 | 7.0 | |
| – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.4 | 0.1 | -16 | 326 | 31 | -8.7 | 59 | 3.2 | 2.2 | 1.8 | – | – | – | |
| 0.1 | 0.0 | 0.1 | -0.2 | 2.8 | -2.0 | 1.6 | -3.1 | -0.6 | -1.6 | 2.7 | 1.6 | -0.5 | 1.1 | -2.4 | 2.3 | 17 | -15 | -0.5 | 3.1 | -4.3 | -2.2 | 0.4 | 0.9 | 29 | -18 | -2.8 | -10 | |
| 3.2 | 0.3 | 0.2 | 0.9 | 2.0 | 0.8 | 7.1 | 0.0 | 0.1 | 1.4 | 1.0 | 1.6 | 0.8 | 0.1 | 0.0 | 0.7 | 1.1 | 2.3 | 4.0 | 7.3 | 1.1 | 0.6 | 0.2 | 0.8 | 0.5 | 1.0 | 0.2 | 0.0 | |
| 7.1 | -3.0 | -13 | -1.9 | 3.0 | 17 | -4.2 | 0.4 | -0.1 | -1.4 | 3.2 | 3.8 | -0.8 | -0.1 | 0.0 | -0.7 | -43 | 7.7 | -99 | 28 | -4.1 | 28 | -15 | -13 | -75 | 51 | 23 | 16 | |
| – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10 | 11 | 12 | 12 | – | – | – | – | |
| – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 33 | 61 | 144 | 0.6 | 49 | 68 | 19 | 87 | 137 | 11 | – | – | – | |
| – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12 | 12 | 12 | 12 | -12 | -12 | – | – | – | – | – | – | – | |
| 0.0 | 20 | 13 | 36 | 9.8 | 21 | 0.8 | -1.2 | -2.9 | 20 | 8.2 | 0.0 | 0.0 | 4.5 | 4.6 | 33 | 61 | 144 | 13 | 49 | 56 | 37 | 87 | 137 | 32 | 31 | 52 | 5.7 | |
| -0.5 | 10 | -8.5 | 24 | -5.4 | 11 | -13 | -15 | -5.6 | 15 | 4.3 | -1.7 | -12 | -3.1 | 38 | 22 | 3.5 | 95 | -143 | 31 | -17 | -5.1 | 20 | 57 | -79 | -4.5 | 10 | -18 | |
| -11 | -7.1 | -8.6 | -11 | -20 | -28 | -17 | -15 | -2.7 | -4.1 | -9.5 | -6.9 | -12 | -7.6 | 33 | -7.5 | -13 | -57 | -62 | -56 | -69 | -72 | -52 | -68 | -36 | -87 | -65 | -40 |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.